Prior to his retirement from the Board of Directors and his operational role in April 2009, David Keiser was President and Chief Operating Officer and a Director of Alexion Pharmaceuticals, a global commercial biopharmaceutical company he co-founded in 1992. In his role at Alexion, Mr. Keiser was responsible for global product marketing and sales, operations, finance and accounting, product development, regulatory affairs, manufacturing and quality functions of the company. He was instrumental in building the company from an early stage development firm into a highly successful and profitable fully-integrated global biopharmaceutical company. From 1990 to 1992, Mr. Keiser was Senior Director of Asia Pacific Operations for G.D. Searle & Company Limited, a manufacturer of pharmaceutical products. From 1986 to 1990, Mr. Keiser was successively Licensing Manager, Director of Product Licensing and Senior Director of Product Licensing for Searle. From 1984 to 1985, Mr. Keiser was New Business Opportunities Manager for Mundipharma AG, a manufacturer of pharmaceutical products, in Basel, Switzerland where he headed pharmaceutical licensing and business development activities in Europe and the Far East. From 1978 to 1983, he was Area Manager for F. Hoffmann La Roche Ltd., a manufacturer of pharmaceutical products, in Basel, Switzerland. Currently, Mr. Keiser advises and serves on the boards of several development stage biotechnology and pharmaceutical companies and co-chairs the executive committee of CURE.
Mr. Keiser is President and managing director of a private foundation and serves on the boards of a number of non-profit charitable organizations.